Free Trial
NASDAQ:NRIX

Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Nurix Therapeutics logo
$11.04 -0.22 (-1.95%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$11.04 0.00 (0.00%)
As of 08/1/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nurix Therapeutics Stock (NASDAQ:NRIX)

Key Stats

Today's Range
$10.86
$11.32
50-Day Range
$9.72
$13.18
52-Week Range
$8.18
$29.56
Volume
533,693 shs
Average Volume
999,154 shs
Market Capitalization
$844.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.87
Consensus Rating
Moderate Buy

Company Overview

Nurix Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

NRIX MarketRank™: 

Nurix Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 517th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nurix Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nurix Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nurix Therapeutics is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nurix Therapeutics is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nurix Therapeutics has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nurix Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    18.25% of the outstanding shares of Nurix Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Nurix Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nurix Therapeutics has recently decreased by 0.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Nurix Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Nurix Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.25% of the outstanding shares of Nurix Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Nurix Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nurix Therapeutics has recently decreased by 0.85%, indicating that investor sentiment is improving.
  • News Sentiment

    Nurix Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    11 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $233,238.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of Nurix Therapeutics is held by insiders.

  • Read more about Nurix Therapeutics' insider trading history.
Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRIX Stock News Headlines

Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.
See More Headlines

NRIX Stock Analysis - Frequently Asked Questions

Nurix Therapeutics' stock was trading at $18.84 on January 1st, 2025. Since then, NRIX shares have decreased by 41.4% and is now trading at $11.04.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its quarterly earnings results on Wednesday, July, 9th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.27. The company earned $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. Nurix Therapeutics had a negative net margin of 234.57% and a negative trailing twelve-month return on equity of 45.26%.

Nurix Therapeutics (NRIX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional investors of Nurix Therapeutics include ARK Investment Management LLC (2.06%), Sumitomo Mitsui Trust Group Inc. (1.82%), AlphaQuest LLC (0.06%) and IQ EQ FUND MANAGEMENT IRELAND Ltd (0.03%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Stefani Wolff.
View institutional ownership trends
.

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

Last Earnings
7/09/2025
Today
8/01/2025
Next Earnings (Estimated)
10/10/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRIX
CIK
1549595
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

High Price Target
$41.00
Low Price Target
$16.00
Potential Upside/Downside
+161.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$193.57 million
Net Margins
-234.57%
Pretax Margin
-233.61%
Return on Equity
-45.26%
Return on Assets
-34.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.82
Quick Ratio
6.82

Sales & Book Value

Annual Sales
$88.38 million
Price / Sales
9.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.85 per share
Price / Book
1.89

Miscellaneous

Outstanding Shares
76,449,000
Free Float
70,792,000
Market Cap
$844.00 million
Optionable
Optionable
Beta
2.15

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:NRIX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners